company background image
BIM logo

bioMérieux ENXTPA:BIM Voorraadrapport

Laatste prijs

€108.20

Marktkapitalisatie

€12.8b

7D

1.5%

1Y

18.1%

Bijgewerkt

02 Oct, 2024

Gegevens

Financiële gegevens bedrijf +

bioMérieux S.A.

ENXTPA:BIM Voorraadrapport

Marktkapitalisatie: €12.8b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

BIM Overzicht aandelen

bioMérieux S.A. ontwikkelt en verkoopt in-vitro diagnostische oplossingen voor de diagnose van infectieziekten in Noord- en Zuid-Amerika, Europa, het Midden-Oosten, Afrika en Azië.

Over het bedrijf

Beloningen

Verhandeld tegen 31.3% onder onze schatting van de reële waarde
De winst zal naar verwachting met 13.68% per jaar groeien
De winst is de afgelopen 5 jaar met 6.3% per jaar gegroeid

Risicoanalyse

Geen risico's gedetecteerd voor BIM uit onze risicocontroles.

bioMérieux S.A. Concurrenten

Klea Holding

ENXTPA:ALKLH

€66.1m

EssilorLuxottica Société anonyme

ENXTPA:EL

€96.6b

Smith & Nephew

LSE:SN.

UK£10.0b

Shanghai United Imaging Healthcare

SHSE:688271

CN¥104.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor bioMérieux
Historische aandelenkoersen
Huidige aandelenkoers€108.20
52 Week Hoogtepunt€111.50
52 Week Laag€84.54
Bèta0.19
11 maand verandering5.66%
3 maanden verandering15.60%
1 Jaar Verandering18.12%
33 jaar verandering11.16%
5 jaar verandering43.50%
Verandering sinds IPO982.00%

Recent nieuws en updates

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

Sep 26
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Aug 03
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Recent updates

bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

Sep 26
bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing

bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Sep 08
bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?

Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

Aug 03
Return Trends At bioMérieux (EPA:BIM) Aren't Appealing

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

May 30
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

Apr 18
Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

Mar 31
bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 17
bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Mar 15
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Jan 27
bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

Jan 06
bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 16
A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Oct 23
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

Oct 05
bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Sep 15
There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Sep 07
Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Jun 30
Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Jun 09
Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Mar 31
Is bioMérieux (EPA:BIM) Using Too Much Debt?

The Return Trends At bioMérieux (EPA:BIM) Look Promising

Feb 23
The Return Trends At bioMérieux (EPA:BIM) Look Promising

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jan 27
Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

Dec 16
bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Oct 18
bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Sep 14
Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Aug 11
Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Jul 23
An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jul 05
Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

May 26
bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

May 11
Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

Apr 23
bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

Apr 09
bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Mar 25
bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Mar 13
Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Feb 08
I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Dec 21
Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 07
Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Nov 07
Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

Oct 07
Is bioMérieux (EPA:BIM) A Risky Investment?

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Sep 22
Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Sep 07
Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Aug 06
Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

Jun 15
There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

May 31
A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Apr 30
Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

bioMérieux (EPA:BIM) Could Easily Take On More Debt

Mar 28
bioMérieux (EPA:BIM) Could Easily Take On More Debt

The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Mar 13
The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Feb 25
Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

Feb 09
If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Jan 20
If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

Dec 30
Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?

Dec 03
Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?

Rendement voor aandeelhouders

BIMFR Medical EquipmentFR Markt
7D1.5%2.4%0.9%
1Y18.1%28.7%5.0%

Rendement versus industrie: BIM presteerde slechter dan de French Medical Equipment -sector, die het afgelopen jaar een rendement van 28.7 % opleverde.

Rendement versus markt: BIM overtrof de French markt, die het afgelopen jaar een rendement opleverde van 5 %.

Prijsvolatiliteit

Is BIM's price volatile compared to industry and market?
BIM volatility
BIM Average Weekly Movement3.3%
Medical Equipment Industry Average Movement5.6%
Market Average Movement4.6%
10% most volatile stocks in FR Market9.6%
10% least volatile stocks in FR Market2.2%

Stabiele aandelenkoers: BIM heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van BIM is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
196313,696Pierre Bouludwww.biomerieux.com

bioMérieux S.A. ontwikkelt en verkoopt in-vitro diagnostische oplossingen voor de diagnose van infectieziekten in Noord- en Zuid-Amerika, Europa, het Midden-Oosten, Afrika en Azië. Het bedrijf biedt CHROMID RANGE, een chromogeen kweekmedium; RAPIDEC CARBA NP biochemische test voor de detectie van carbapenemaseproducerende bacteriën; lucht-, oppervlakte- en waterbewakingssystemen; BACT/ALERT VIRTUO BACT/ALERT 3D, een kweeksysteem voor bloedmonsters; BIOFIRE, een multiplex polymerasekettingreactiesysteem (PCR); BIOFIRE SPOTFIRE Lowplex PCR point-of-care systeem; VITEK MS, een massaspectrometriesysteem; VITEK 2, een geautomatiseerd systeem voor identificatie en antimicrobiële gevoeligheidstests (AST); API RANGE gestandaardiseerde ID-strips; VITEK REVEAL Rapid AST-systeem; ETEST Gradient-methode op kweekmedia; BIOMERIEUX EPISEQ CS whole genome sequencing oplossing voor epidemiologische monitoring; en VIDASB-R-A-H-M-S PCTTM, een specifieke marker van ernstige bacteriële infecties/sepsis. Het biedt ook Biomérieux vision suite, software die bruikbare informatie biedt ter ondersteuning van diagnose en klinische besluitvorming; kweekmedia en bijbehorende instrumenten; ARGENE Monoplex PCR-tests; NUCLISENS assortimenten, een product voor automatisering van het moleculair biologisch laboratorium en extractie; EMAG-systeem voor DNA- en RNA-extractie; ESTREAM, een geautomatiseerd voorbereidingsstation voor monsters om PCR-tests te verwerken; GENE-UP en VERIFLOW assortimenten voor detectie van micro-organismen voor de voedingsindustrie.

bioMérieux S.A. Samenvatting

Hoe verhouden de winst en inkomsten van bioMérieux zich tot de beurswaarde?
BIM fundamentele statistieken
Marktkapitalisatie€12.77b
Inkomsten(TTM)€411.30m
Inkomsten(TTM)€3.81b

31.0x

Koers/Winstverhouding

3.4x

P/S-verhouding

Is BIM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BIM resultatenrekening (TTM)
Inkomsten€3.81b
Kosten van inkomsten€1.69b
Brutowinst€2.12b
Overige uitgaven€1.71b
Inkomsten€411.30m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)3.49
Brutomarge55.72%
Nettowinstmarge10.81%
Schuld/Eigen Vermogen Verhouding10.1%

Hoe presteerde BIM op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.8%

Huidig dividendrendement

24%

Uitbetalingsratio